With health technology assessment organisations becoming more powerful in Europe, and huge public scrutiny on drug prices in the US, it’s vitally important that pharma companies start thinking about the value of their product early in development. Richard Staines from pharmaphorum spoke with Rosanne Campbell and Andrew Thomas from Syneos Health to find out more.
This content was repurposed from pharmaphorum.
